BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23497641)

  • 1. Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.
    Sardinha R; Hernández T; Fraile S; Tresserra F; Vidal A; Gómez MC; Astudillo A; Hernández N; Saenz de Santamaría J; Ordi J; Gonçalves L; Ramos R; Balañá C; de Álava E
    Clin Sarcoma Res; 2013 Mar; 3(1):3. PubMed ID: 23497641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
    Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
    Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
    J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
    Longatto-Filho A; Pinheiro C; Martinho O; Moreira MA; Ribeiro LF; Queiroz GS; Schmitt FC; Baltazar F; Reis RM
    BMC Cancer; 2009 Jun; 9():212. PubMed ID: 19563658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma.
    Swick BL; Srikantha R; Messingham KN
    J Cutan Pathol; 2013 Jul; 40(7):623-30. PubMed ID: 23621836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
    Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
    Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of pediatric gastrointestinal stromal tumors.
    Agaram NP; Laquaglia MP; Ustun B; Guo T; Wong GC; Socci ND; Maki RG; DeMatteo RP; Besmer P; Antonescu CR
    Clin Cancer Res; 2008 May; 14(10):3204-15. PubMed ID: 18483389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene alterations in endometrial carcinosarcomas.
    Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
    Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
    Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
    J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of mutation of the c-Kit gene and
    Xu CW; Lin S; Wang WL; Gao WB; Lv JY; Gao JS; Zhang LY; Li Y; Wang L; Zhang YP; Tian YW
    Exp Ther Med; 2015 Sep; 10(3):1045-1051. PubMed ID: 26622437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal stromal tumors: morphological, immunohistochemical and molecular changes associated with kinase inhibitor therapy.
    Díaz Delgado M; Hernández Amate A; Pereira Gallardo S; Jaramillo S; Virizuela Echaburu JA; González-Cámpora RJ
    Pathol Oncol Res; 2011 Sep; 17(3):455-61. PubMed ID: 21279555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
    Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS
    Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
    Medeiros F; Corless CL; Duensing A; Hornick JL; Oliveira AM; Heinrich MC; Fletcher JA; Fletcher CD
    Am J Surg Pathol; 2004 Jul; 28(7):889-94. PubMed ID: 15223958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.